Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Edward Li, PharmD, MPH
Advertisement
Articles by Edward Li, PharmD, MPH
Advertisement
Latest Updated Articles
Budget Impact Analysis of Biosimilar Natalizumab in the USPublished: May 17th 2024 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Digital, Blood-Based Innovations Transform Alzheimer Disease Detection: Ken Cohen, MD, FACP
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
4
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
5
